Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge

References

• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209–220.
   PubMed Web of Science ®Google Scholar
• Hsu C, Hsiung CA, Su IJ, et al A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008;47:844–853.
   PubMed Web of Science ®Google Scholar
• Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182–188.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 1996;78:2210–2215.
   PubMed Web of Science ®Google Scholar
• Yeo W, Lam KC, Zee B, et al Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661–1666.
   PubMed Web of Science ®Google Scholar
• Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999;17:394–398.
   PubMed Web of Science ®Google Scholar
• Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963–977.
   PubMed Web of Science ®Google Scholar
• Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998;13:14–20.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Zhong S, et al Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299–307.
   PubMed Web of Science ®Google Scholar
• Kumagai K, Takagi T, Nakamura S, et al Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8(Suppl. 1):107–109.
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83:1627–1631.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsiung CA, Su IJ, et al Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320–1328.
   PubMed Web of Science ®Google Scholar
• Hsu CH, Hsu HC, Chen HL, et al Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res 2004;24:3035–3040.
   Google Scholar
• Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004;83:769–774.
   PubMed Web of Science ®Google Scholar
• Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68–69.
   PubMed Web of Science ®Google Scholar
• Westhoff TH, Jochimsen F, Schmittel A, et al Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605–611.
   PubMed Web of Science ®Google Scholar
• Li X, Lin Q, Dong M, et al Prognostic analysis of acute exacerbations of hepatitis B after chemotherapy in combination with rituximab in 19 patients wtih lymphoma. Leuk Lymphoma 2010;51:1678–1685.
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998–1005.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–242.
   PubMed Web of Science ®Google Scholar
• Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104–1108.
   PubMed Web of Science ®Google Scholar
• Yuki N, Nagaoka T, Yamashiro M, et al Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003;37:1172–1179.
   PubMed Web of Science ®Google Scholar
• Targhetta C, Cabras MG, Angelucci E. Risk of HBV liver disease in isolated antiHbc patients receiving immuno-chemotherapy for non Hodgkin lymphoma. Haematologica 2008;93:e66.
   PubMedGoogle Scholar
• Koo YX, Tan DS, Tan BH, Quek R, Tao M, Lim ST. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis. J Clin Oncol 2009;27:2570–2571; author reply 2571–2572.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Hui P, et al Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553–561.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–662.
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Au WY, et al Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005;54:1597–1603.
   PubMed Web of Science ®Google Scholar
• Li YH, He YF, Jiang WQ, et al Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320–1325.
   PubMed Web of Science ®Google Scholar
• Chtioui H, Millius C, Lammle B, Lauterberg BH. Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. Br J Haematol 2009;144:136–137.
   PubMed Web of Science ®Google Scholar
• Brunton, L, Lazo, JS, Parker, KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2006.
   Google Scholar